• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Safety and Efficacy of Vedolizumab in Kidney Transplant Recipients With Crohn's Disease.

作者信息

Busutti Marco, Baraldi Olga, Porcu Clara Valentina, Samele Gianluca, Campus Anita, Grandinetti Valeria, Bini Claudia, Provenzano Michele, Dussias Nikolas, Rizzello Fernando, Gionchetti Paolo, La Manna Gaetano, Comai Giorgia

机构信息

Nephrology, Dialysis and Renal Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Nephrology Unit, Department of Medical and Surgical Science (DIMEC), Alma Mater Studiorum University of Bologna, Bologna, Italy.

出版信息

Kidney Int Rep. 2023 May 9;8(8):1676-1679. doi: 10.1016/j.ekir.2023.05.004. eCollection 2023 Aug.

DOI:10.1016/j.ekir.2023.05.004
PMID:37547522
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10403642/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ed/10403642/4aaf32901133/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ed/10403642/4aaf32901133/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ed/10403642/4aaf32901133/gr1.jpg

相似文献

1
Safety and Efficacy of Vedolizumab in Kidney Transplant Recipients With Crohn's Disease.维多珠单抗在克罗恩病肾移植受者中的安全性和有效性
Kidney Int Rep. 2023 May 9;8(8):1676-1679. doi: 10.1016/j.ekir.2023.05.004. eCollection 2023 Aug.
2
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.英夫利昔单抗与维得利珠单抗治疗炎症性肠病患者的疗效和安全性比较：系统评价和荟萃分析。
BMC Gastroenterol. 2022 Jun 8;22(1):291. doi: 10.1186/s12876-022-02347-1.
3
A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhagen, Denmark• VARSITY: A Double-Blind, Double-Dummy, Randomized Controlled Trial of Vedolizumab Versus Adalimumab in Patients With Active Ulcerative Colitis• Analyses of Data From the VISIBLE 1 and 2 Trials: Vedolizumab in Patients With Ulcerative Colitis or Crohn's Disease• Improved Endoscopic Outcomes and Mucosal Healing of Upadacitinib as an Induction Therapy in Adults With Moderately to Severely Active Ulcerative Colitis: Data From the U-ACHIEVE Study• Long-Term Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease: Final Results From the GEMINI LTS Study• Pediatric Crohn's Disease Adalimumab Level-Based Optimization Treatment (PAILOT) Randomized Controlled Trial• Maintenance Treatment With Mirikizumab, a P19-Directed IL-23 Antibody: 52-Week Results in Patients With Moderately to Severely Active Ulcerative Colitis• Real-World Effectiveness and Safety of Vedolizumab and Anti-TNF Therapy in Biologic-Naive Patients With Ulcerative Colitis or Crohn's Disease: Results From the EVOLVE Study• A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of a Targeted-Release Oral Cyclosporine Formulation in the Treatment of Mild to Moderate Ulcerative Colitis: Efficacy Results• Real-World Analyses of Patients With IBD Treated With Vedolizumab Professor of MedicineDivision of Gastroenterology and HepatologyMayo ClinicRochester, Minnesota.特别会议回顾版：欧洲克罗恩病和结肠炎组织（ECCO）第14届大会炎症性肠病亮点：对第14届欧洲克罗恩病和结肠炎组织（ECCO）大会部分演讲的回顾 • 2019年3月6 - 9日 • 丹麦哥本哈根• VARSITY：维多珠单抗与阿达木单抗治疗活动性溃疡性结肠炎患者的双盲、双模拟、随机对照试验• 来自VISIBLE 1和2试验的数据分析：维多珠单抗治疗溃疡性结肠炎或克罗恩病患者• 乌帕替尼作为中度至重度活动性溃疡性结肠炎成人诱导治疗的内镜结果改善和黏膜愈合：U - ACHIEVE研究数据• 维多珠单抗治疗溃疡性结肠炎和克罗恩病的长期安全性：GEMINI LTS研究最终结果• 儿童克罗恩病阿达木单抗基于水平的优化治疗（PAILOT）随机对照试验• 抗P19导向的IL - 23抗体mirikizumab维持治疗：中度至重度活动性溃疡性结肠炎患者52周结果• 维多珠单抗和抗TNF治疗在初治溃疡性结肠炎或克罗恩病患者中的真实世界有效性和安全性：EVOLVE研究结果• 靶向释放口服环孢素制剂治疗轻至中度溃疡性结肠炎的随机、多中心、双盲、安慰剂对照研究：疗效结果• 接受维多珠单抗治疗的炎症性肠病患者的真实世界分析 医学教授 胃肠病学和肝病科 梅奥诊所 明尼苏达州罗切斯特
Gastroenterol Hepatol (N Y). 2019 May;15(5 Suppl 2):1-24.
4
Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study.乌司奴单抗与维多珠单抗在老年炎症性肠病患者中的安全性比较：一项双中心队列研究。
J Clin Med. 2022 Nov 25;11(23):6967. doi: 10.3390/jcm11236967.
5
Vedolizumab (Entyvio®) for the Treatment of Pyoderma Gangrenosum in a Crohn's Disease Patient.维多珠单抗（恩特维尤®）用于治疗一名克罗恩病患者的坏疽性脓皮病。
Cureus. 2021 Jan 8;13(1):e12582. doi: 10.7759/cureus.12582.
6
Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn's Disease: A Post Hoc Analysis of GEMINI 2 and 3.维得利珠单抗联合皮质类固醇用于克罗恩病的诱导治疗：GEMINI 2 和 3 的事后分析。
Inflamm Bowel Dis. 2019 Jul 17;25(8):1375-1382. doi: 10.1093/ibd/izy384.
7
The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data.维得利珠单抗在溃疡性结肠炎和克罗恩病中的安全性：全球上市后 4 年的数据。
J Crohns Colitis. 2020 Feb 10;14(2):192-204. doi: 10.1093/ecco-jcc/jjz137.
8
Postoperative outcomes in vedolizumab-treated Crohn's disease patients undergoing major abdominal operations.接受维得利珠单抗治疗的克罗恩病患者行大型腹部手术后的术后结局。
Aliment Pharmacol Ther. 2018 Mar;47(5):573-580. doi: 10.1111/apt.14459. Epub 2017 Dec 18.
9
Use of Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience.使用维得利珠单抗治疗炎症性肠病：单中心经验。
Turk J Gastroenterol. 2022 Oct;33(10):831-837. doi: 10.5152/tjg.2022.21684.
10
Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age.维多珠单抗在按年龄分层的溃疡性结肠炎和克罗恩病患者中的疗效与安全性。
Adv Ther. 2017 Feb;34(2):542-559. doi: 10.1007/s12325-016-0467-6. Epub 2017 Jan 9.

本文引用的文献

1
Renal manifestations in inflammatory bowel disease: a systematic review.炎症性肠病的肾脏表现：系统评价。
J Gastroenterol. 2022 Sep;57(9):619-629. doi: 10.1007/s00535-022-01903-6. Epub 2022 Jul 14.
2
Treatment of Inflammatory Bowel Disease: A Comprehensive Review.炎症性肠病的治疗：全面综述
Front Med (Lausanne). 2021 Dec 20;8:765474. doi: 10.3389/fmed.2021.765474. eCollection 2021.
3
Long-term safety of vedolizumab for inflammatory bowel disease.维得利珠单抗治疗炎症性肠病的长期安全性。
Aliment Pharmacol Ther. 2020 Oct;52(8):1353-1365. doi: 10.1111/apt.16060. Epub 2020 Sep 2.
4
Increased end-stage renal disease risk in patients with inflammatory bowel disease: A nationwide population-based study.炎症性肠病患者终末期肾病风险增加：一项全国范围内基于人群的研究。
World J Gastroenterol. 2018 Nov 14;24(42):4798-4808. doi: 10.3748/wjg.v24.i42.4798.
5
Management of Tumor Necrosis Factor α Inhibitor Therapy After Renal Transplantation: A Comparative Analysis and Associated Outcomes.移植肾后肿瘤坏死因子 α 抑制剂治疗的管理：比较分析及相关结局。
Ann Pharmacother. 2019 Mar;53(3):268-275. doi: 10.1177/1060028018802814. Epub 2018 Sep 20.
6
How to measure and monitor albuminuria in healthy toddlers?如何在健康的幼儿中测量和监测蛋白尿？
PLoS One. 2018 Jun 21;13(6):e0199309. doi: 10.1371/journal.pone.0199309. eCollection 2018.
7
Ulcerative colitis.溃疡性结肠炎。
Lancet. 2017 Apr 29;389(10080):1756-1770. doi: 10.1016/S0140-6736(16)32126-2. Epub 2016 Dec 1.
8
Crohn's disease.克罗恩病。
Lancet. 2017 Apr 29;389(10080):1741-1755. doi: 10.1016/S0140-6736(16)31711-1. Epub 2016 Dec 1.
9
Anti-TNFα therapy for chronic inflammatory disease in kidney transplant recipients: Clinical outcomes.抗TNFα疗法用于肾移植受者慢性炎症性疾病：临床结局
Medicine (Baltimore). 2016 Oct;95(41):e5108. doi: 10.1097/MD.0000000000005108.